Literature DB >> 22110227

Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.

Soichi Tsutsumi1, Yuichi Tabe, Takaaki Fujii, Satoru Yamaguchi, Toshinaga Suto, Reina Yajima, Hiroki Morita, Toshihide Kato, Mariko Shioya, Jun-Ichi Saito, Takayuki Asao, Takashi Nakano, Hiroyuki Kuwano.   

Abstract

BACKGROUND: The safety of regional hyperthermia has been tested in locally advanced rectal cancer. The aim of this study was to assess the effects of shorter distal margins on local control and survival in rectal cancer patients who were treated with preoperative hyperthermochemoradiation therapy (HCRT) and underwent rectal resection by using the total mesorectal excision (TME) method. PATIENTS AND METHODS: Ninety-three patients with rectal adenocarcinoma who received neoadjuvant HCRT (total radiation: 50 Gy) were included in this study. Surgery was performed 8 weeks after HCRT, and each resected specimen was evaluated histologically. Length of distal surgical margins, status of circumferential margins, pathological response, and tumor node metastasis stage were examined for their effects on recurrence and survival.
RESULTS: Fifty-eight (62.4%) patients had tumor regression, and 20 (21.5%) had a pathological complete response. Distal margin length ranged from 1 to 55 mm (median, 21 mm) and did not correlate with local recurrence (p=0.57) or survival (p=0.75) by univariate analysis. Kaplan-Meier estimates of recurrence-free survival and local recurrence for the <10 mm versus ≥10 mm groups were not significantly different. Positive circumferential margins and failure of tumors to respond were unfavorable factors in survival.
CONCLUSION: Distal resection margins that are shorter than 10 mm but are not positive appear to be equivalent to longer margins in patients who undergo HCRT followed by rectal resection with TME. To improve the down-staging rate, additional studies are needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22110227

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study.

Authors:  Hisanori Shoji; Masahiko Motegi; Kiyotaka Osawa; Noriyuki Okonogi; Atsushi Okazaki; Yoshitaka Andou; Takayuki Asao; Hiroyuki Kuwano; Takeo Takahashi; Kyoji Ogoshi
Journal:  Cancer Med       Date:  2015-02-09       Impact factor: 4.452

2.  HLA class I expression and its alteration by preoperative hyperthermo-chemoradiotherapy in patients with rectal cancer.

Authors:  Hiro Sato; Yoshiyuki Suzuki; Munenori Ide; Toshihide Katoh; Shin-Ei Noda; Ken Ando; Takahiro Oike; Yuya Yoshimoto; Noriyuki Okonogi; Kousaku Mimura; Takayuki Asao; Hiroyuki Kuwano; Takashi Nakano
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

3.  Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis.

Authors:  Akiharu Kimura; Kyoichi Ogata; Bolag Altan; Takehiko Yokobori; Erito Mochiki; Mitsuhiro Yanai; Norimichi Kogure; Toru Yanoma; Masaki Suzuki; Tuya Bai; Hiroyuki Kuwano
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

4.  Outcomes of surgical treatment in patients with anorectal fistula cancer.

Authors:  Katsuya Osone; Hiroomi Ogawa; Chika Katayama; Yuta Shibasaki; Kunihiko Suga; Chika Komine; Naoya Ozawa; Takuhisa Okada; Takuya Shiraishi; Ryuji Katoh; Makoto Sakai; Akihiko Sano; Takehiko Yokobori; Nozomi Matsumura; Makoto Sohda; Ken Shirabe; Hiroshi Saeki
Journal:  Surg Case Rep       Date:  2021-01-26

5.  Long-Term Feasibility of 13.56 MHz Modulated Electro-Hyperthermia-Based Preoperative Thermoradiochemotherapy in Locally Advanced Rectal Cancer.

Authors:  Yohan Lee; Sunghyun Kim; Hyejung Cha; Jae Hun Han; Hyun Joon Choi; Eun Go; Sei Hwan You
Journal:  Cancers (Basel)       Date:  2022-03-01       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.